Ken Griffin Seelos Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$0.16 - $1.64 $4,512 - $46,248
28,200 Added 98.26%
56,900 $10,000
Q2 2023

Aug 14, 2023
BUY
$0.66 - $1.22 $6,732 - $12,444
10,200 Added 55.14%
28,700 $34,000
Q1 2023

May 15, 2023
SELL
$0.59 - $1.04 $34,515 - $60,840
-58,500 Reduced 75.97%
18,500 $12,000
Q4 2022

Feb 14, 2023
SELL
$0.66 - $259.46 $31,680 - $12.5 Million
-48,000 Reduced 38.4%
77,000 $52,000
Q3 2022

Nov 14, 2022
BUY
$0.65 - $278.68 $57,850 - $24.8 Million
89,000 Added 247.22%
125,000 $129,000

Others Institutions Holding SEEL

# of Institutions
1
Shares Held
40.5K
Call Options Held
0
Put Options Held
0
View Full List

About SEELOS THERAPEUTICS, INC.

SEEL Quotes by TradingView
  • Ticker SEEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 106,691,000
  • Market Cap $117M
  • Description
  • Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in...
More about SEEL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email